Skip to main content
Log in

Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Mixture models are applied in population pharmacometrics to characterize underlying population distributions that are not adequately approximated by a single normal or lognormal distribution. In addition to obtaining individualized maximum a posteriori Bayesian post hoc parameter estimates, the subpopulation to which an individual was classified can be determined. However, the accuracy of the classification of subjects to subpopulations is not well studied. We investigated the impact of several factors on the accuracy of classification in mixture models applied to pharmacokinetics using a simulation strategy. The availability of actual subject data allowed us to evaluate mixture model classification in a potentially common application, namely, the classification of clearance into poor metabolizer (PM) or extensive metabolizer (EM) subgroups with the known phenotype status in subjects receiving metoprolol. The factors explored in the simulation study were the magnitude of difference between the clearances in two subpopulations, the between subject variability in clearance, the mixing-fraction, and the population sample size. Populations were simulated at various levels of the above factors and analyzed with a mixture model using NONMEM. The population pharmacokinetics of metoprolol were modeled with the EM/PM phenotype as a known covariate, and without the phenotype covariate using a mixture model. Within the range of scenarios studied, the proportion of subjects classified into the correct subpopulation was high. The simulation–estimation study suggests that a greater separation between two subpopulations, a smaller variability in the parameter distribution, a larger sample size, and a smaller size subpopulation tend to be associated with a greater accuracy of subpopulation classification when a mixture model is applied to pharmacokinetic data. In a population pharmacokinetic analysis of metoprolol, a drug that undergoes polymorphic metabolism, it was possible to correctly identify phenotype status using a mixture model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hussein R., Charles B.G., Morris R.G., Rasiah R.L. (2001) Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther. Drug Monit. 23:636–643

    Article  PubMed  CAS  Google Scholar 

  2. Frame B., Miller R., Lalonde R.L. (2003) Evaluation of mixture modeling with count data using NONMEM. J. Pharmacokinet. Pharmacodyn. 30:167–183

    Article  PubMed  CAS  Google Scholar 

  3. Facca B., Frame B., Triesenberg S. (1998) Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. Antimicrob. Agents Chemother. 42:1783–1787

    PubMed  CAS  Google Scholar 

  4. Borg K.O. et al. (1975) Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol. Toxicol. (Copenh). 36(Suppl):125–135

    CAS  Google Scholar 

  5. Otton S.V., Crewe H.K., Lennard M.S., Tucker G.T., Woods H.F. (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247:242–247

    PubMed  CAS  Google Scholar 

  6. Johnson J.A., Burlew B.S. (1996). Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab. Dispos. 24:350–355

    PubMed  CAS  Google Scholar 

  7. http://www.imm.ki.se/CYPalleles/. Human cytochrome P450 (CYP) allele nomenclature committee. Criteria for inclusion, and nomenclature files [online].

  8. Streetman D.S., Bertino J.S. Jr., Nafziger A.N. (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216

    Article  PubMed  CAS  Google Scholar 

  9. Alvan G., Bechtel P., Iselius L., Gundert-Remy U. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39:533–537

    Article  PubMed  CAS  Google Scholar 

  10. Bertilsson L., Dahl M.L. (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5:200–223

    Article  CAS  Google Scholar 

  11. Bertilsson L. et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51:388–397

    Article  PubMed  CAS  Google Scholar 

  12. Evans D.A., Mahgoub A., Sloan T.P., Idle J.R., Smith R.L. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 17:102–105

    Article  PubMed  CAS  Google Scholar 

  13. Johansson I. et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90:11825–11829

    Article  PubMed  CAS  Google Scholar 

  14. Dahl M.L., Johansson I., Palmertz M.P., Ingelman-Sundberg M., Sjoqvist F. (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 51:12–17

    Article  PubMed  CAS  Google Scholar 

  15. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., Sjoqvist F. (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274:516–520

    CAS  Google Scholar 

  16. Wikstrand J. et al. (1988) Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976–1982

    Article  PubMed  CAS  Google Scholar 

  17. Straka R.J., Johnson K.A., Gross C.R., Brundage R.C., McBride J.W. (1991) Pharmacodynamic modeling of metoprolol enantiomers in poor and extensive metabolizers of debrisoquin. Clin. Pharmacol. Ther. 49:157

    Google Scholar 

  18. Straka R.J., Marshall P.S., Johnson K.A., Carr J.C., McBride J.W. (1992) The effects of smoking on post exercise heart rate and metoprolol enantiomeric pharmacodynamics in extensive metabolisers of dextromethorphan. Pharmacotherapy 12(3):1992

    Google Scholar 

  19. Straka R.J., Johnson K.A., Marshall P.S., Remmel R.P. (1990) Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. J. Chromatogr. 530:83–93

    Article  PubMed  CAS  Google Scholar 

  20. Straka R.J., Hansen S.R., Walker P.F. (1995) Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol. Ther. 58:29–34

    Article  PubMed  CAS  Google Scholar 

  21. Kirchheiner J. et al. (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76:302–312

    Article  PubMed  CAS  Google Scholar 

  22. Zineh I. et al. (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76:536–544

    Article  PubMed  CAS  Google Scholar 

  23. Schaaf L.J., Dobbs B.R., Edwards I.R., Perrier D.G. (1987) Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur. J. Clin. Pharmacol. 32:411–418

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard C. Brundage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaila, N., Straka, R.J. & Brundage, R.C. Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype. J Pharmacokinet Pharmacodyn 34, 141–156 (2007). https://doi.org/10.1007/s10928-006-9038-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-006-9038-9

Keywords

Navigation